Cathal Friel, Executive Chairman of Open Orphan (ORPH.L) Shareholder Update

With the Launch of Covid-19 Antibody Testing announced in June, Major New Contract Signed, it has been a blistering start to the month.

Cathal Friel, Executive Chairman gave this exclusive interview and he is confident that further news is just around the corner.

Open Orphan plc (ORPH) is a rapidly growing niche CRO pharmaceutical services company which is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical trials. Open Orphan comprises of two commercial specialist CRO services businesses; hVIVO and Venn Life Sciences and has offices in London, Dublin, Paris, and the Netherlands. Open Orphan is led by a management team with deep industry and financial experience

Cathal Friel, Executive Chairman of Open Orphan, said:

“hVIVO is a world-class company with best in class scientists and facilities. We are very excited to be offering this service and I am confident our work will help large companies and clinics in the UK test their staff and patients to ensure the safety of all employees. These are run from its 24-bedroom quarantine clinic in London, with an onsite virology laboratory.

See www.flucamp.com to see how volunteers are managed.

Company Website www.openorphan.com

Twitter @OpenOrphan


Linking Shareholders and Executives :Share Talk

If anyone reads this article found it useful, helpful? Then please subscribe www.share-talk.com or follow SHARE TALK on our Twitter page for future updates. Terms of Website Use All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned
Share via
Copy link
Malcare WordPress Security